U.S. Markets closed

Immunic, Inc. (IMUX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.83-0.34 (-3.71%)
At close: 4:00PM EDT
8.83 0.00 (0.00%)
After hours: 04:03PM EDT
Full screen
Loading interactive chart...
  • Immunic, Inc. Announces Closing of $45.0 Million Public Offering
    PR Newswire

    Immunic, Inc. Announces Closing of $45.0 Million Public Offering

    Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $10.00 per share.

  • Why Immunic Plummeted by 21% on Thursday
    Motley Fool

    Why Immunic Plummeted by 21% on Thursday

    The company announced a planned new share issue that had many investors heading to the exits, and drove the stock down by more than 21% on the day. Immunic aims to raise gross proceeds of around $45 million by selling 4.5 million shares of common stock at $10 apiece in an underwritten public offering. The underwriting syndicate, led by Piper Sandler (NYSE: PIPR), has been granted a 30-day option to buy up to an extra 675,000 shares among themselves.

  • Immunic Stock Is Trading Lower After Equity Raise Of $45M To Fund Lead Pipeline Candidates
    Benzinga

    Immunic Stock Is Trading Lower After Equity Raise Of $45M To Fund Lead Pipeline Candidates

    Immunic Inc (NASDAQ: IMUX) has priced an underwritten public offering of 4.5 million shares at per share, representing a discount of about 16% from the last close price of $11.89 on Wednesday. The gross proceeds are expected to be approximately $45 million. Underwriters have an option to purchase up to an additional 675,000 shares. The offering will close by July 19. Piper Sandler is acting as the sole book-runner for the offering. Ladenburg Thalmann & Co. Inc., Roth Capital Partners, and Aegis